Clinical Trials Update from NCI, March 2023

National Cancer Institute banner

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

Clinical Trials
Updates from the National Cancer Institute
Clinical Trials News
bladder image  

Immunotherapy after Surgery Shows Long-Term Benefits for High-Risk Bladder Cancer

Updated results from a large clinical trial confirm that, for some people with bladder cancer, receiving immunotherapy after surgery is an effective treatment. In 2021, initial results from the same trial led to Food and Drug Administration approval of nivolumab (Opdivo) for this use.

Surgical team  

Lung-Sparing Surgery Is Effective for Some with Early-Stage Lung Cancer

Results from a large clinical trial show that surgery to remove a piece of the lung lobe is as effective as surgery to remove the whole lobe.

Clinical Trials Information for Patients and Caregivers

Clinical Trial Terms from the NCI Dictionary of Cancer Terms

Cancer clinical trials are often described in terms unfamiliar to people without a medical background. The terms below are often used to talk about types of clinical trials.

Clinical trials search  

Find NCI-Supported Clinical Trials


Use our search form to find a clinical trial or other research study that may be right for you or a loved one.

NCI-Supported Clinical Trials That Are Recruiting Patients 

Combining Immunotherapies for Advanced Melanoma or Head and Neck Cancer

This phase 2 trial will test the effectiveness of combining nivolumab (Opdivo) and cabozantinib (Cabometyx) to treat people with melanoma or squamous cell head and neck cancer that has spread. This trial may help doctors determine how quickly patients can be divided into groups based on biomarkers in their tumors.


Testing an Internet Intervention to Help Cancer Patients Control Pain

This phase 3 clinical trial will test an internet-based program of coping skills for pain in adults with cancer. People undergoing adjuvant treatment or who have finished cancer treatment but are still experiencing pain will be randomly assigned to receive the internet-based program along with standard care, or standard care alone. Doctors want to see if the internet-based program reduces the pain and the amount of interference it causes in daily life.


Comparing Immunotherapy Dosing Intervals for Advanced or Metastatic Cancer

This phase 1 trial will test an immune checkpoint inhibitor treatment, either nivolumab (Opdivo) or pembrolizumab (Keytruda), given at different dosing intervals for people with advanced or metastatic cancers. Doctors want to determine if giving the drugs at longer intervals between doses works differently than giving them at the usual intervals.